期刊文献+

An optimized micro-assay of myosin Ⅱ ATPase activity based on the molybdenum blue method and its application in screening natural product inhibitors

An optimized micro-assay of myosin Ⅱ ATPase activity based on the molybdenum blue method and its application in screening natural product inhibitors
原文传递
导出
摘要 Myosin Ⅱ plays multiple roles in physiological and pathological functions through its ATPase activity. The present study was designed to optimize a micro-assay of myosin Ⅱ ATPase activity based on molybdenum blue method, using a known myosin Ⅱ ATPase inhibitor, blebbistatin. Several parameters were observed in the enzymatic reaction procedure, including the concentrations of the substrate(ATP) and calcium chloride, p H, and the reaction and incubation times. The proportion of coloration agent was also investigated. The sensitivity of this assay was compared with the malachite green method and bioluminescence method. Additionally, 20 natural compounds were studied for myosin Ⅱ ATPase inhibitory activity using the optimized method. Our results showed that ATP at the concentration of 5 mmol·L^(-1) and ammonium molybdate : stannous chloride at the ratio of 15 : 1 could greatly improve the sensitivity of this method. The IC50 of blebbistatin obtained by this method was consistent with literature. Compound 8 was screened with inhibitory activity on myosin Ⅱ ATPase. The optimized method showed similar accuracy, lower detecting limit, and wider linear range, which could be a promising approach to screening myosin Ⅱ ATPase inhibitors in vitro. Myosin Ⅱ plays multiple roles in physiological and pathological functions through its ATPase activity. The present study was designed to optimize a micro-assay of myosin Ⅱ ATPase activity based on molybdenum blue method, using a known myosin Ⅱ ATPase inhibitor, blebbistatin. Several parameters were observed in the enzymatic reaction procedure, including the concentrations of the substrate(ATP) and calcium chloride, p H, and the reaction and incubation times. The proportion of coloration agent was also investigated. The sensitivity of this assay was compared with the malachite green method and bioluminescence method. Additionally, 20 natural compounds were studied for myosin Ⅱ ATPase inhibitory activity using the optimized method. Our results showed that ATP at the concentration of 5 mmol·L-1 and ammonium molybdate : stannous chloride at the ratio of 15 : 1 could greatly improve the sensitivity of this method. The IC50 of blebbistatin obtained by this method was consistent with literature. Compound 8 was screened with inhibitory activity on myosin Ⅱ ATPase. The optimized method showed similar accuracy, lower detecting limit, and wider linear range, which could be a promising approach to screening myosin Ⅱ ATPase inhibitors in vitro.
出处 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2016年第6期421-426,共6页 中国天然药物(英文版)
基金 supported by National Natural Science Foundation of China(No.81274131) the Graduate Student Innovation Plan of Jiangsu Province(CXLX11_0784) Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions 2011 Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education
关键词 Myosin ATPase activity BLEBBISTATIN BIOLUMINESCENCE Natural products Malachite green Myosin Ⅱ ATPase activity Blebbistatin Bioluminescence Natural products Malachite green
  • 相关文献

参考文献1

二级参考文献41

  • 1Sellers JR. Myosins: a diverse superfamily [J]. Biochim Biophys Acta, 2000,1496 (1 i}:3-22.
  • 2Conti MA, Adelstein RS. Nonmuscle myosin Ⅱ moves in new directions [J]. J Cell Sci, 2008,121 (1):11-18.
  • 3Sellers JR, Goodson HV. Motor proteins 2: myosin[J]. Protein Profile, 1995, 2 (12):1323-1423.
  • 4Golomb E, Ma X, Jana SS, et al. Identification and characterization of nonmuscle myosin Ⅱ-C, a new member of the myosin Ⅱ family [J]. J Biol Chem, 2004, 279 (4):2800-2808.
  • 5Kelley M J, Jawien W, Ortel TL, et al. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly [J]. Nat Genet, 2000,26 (1):106-108.
  • 6Toren A, Rozenfeld-Granot G, Rocca B, et al. Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13[J]. Blood, 2000,96 (10):3447-3451.
  • 7Seri M, Pecci A, Di Bari F, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness[J]. Medicine (Baltimore), 2003,82 (3):203-215.
  • 8Althaus K, Greinacher A. MYH9-related platelet disorders [J]. Semin Thromb Hemost, 2009,35 (2): 189-203.
  • 9Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia [J]. Br J Haematol,2005,130 (4): 620-627.
  • 10Kunishima S, Matsushita T, Hamaguchi M, et al. Identification and characterization of the first large deletion of the MYH9 gene associated with MYH9 disorders [J]. Eur J Haematol, 2008, 80(6): 540-4.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部